CTRAI2 project kick-off

We want to share with you the launch of CTRAI2 – AI-based Risk Assessment for Clinical Trials on Medicinal Products: A Large-Scale and Integrative Approach, whose kick-off meeting was held on 15 April 2026. Supported by the Swiss National Science Foundation (project funding, CHF 727,500) for the period April 2026 – March 2030, CTRAI2 is jointly led by Prof. Douglas Teodoro (PI, Data Science for Digital Health, Faculty of Medicine, UNIGE) and Prof. Caroline Samer (co-PI, Division of Clinical Pharmacology and Toxicology, HUG and UNIGE).

Clinical trials remain a cornerstone of drug development, yet they are costly and frequently affected by high failure rates. CTRAI2 will develop an integrative AI-based framework for the joint assessment of safety, efficacy and operational risks in clinical trials, building on a large-scale benchmark dataset derived from trial protocols, results and related biomedical sources, together with deep learning models tailored to this setting. By bringing together clinical pharmacology and data science expertise, the project aims to contribute to more reliable risk prediction, improved trial design and safer, more efficient drug development. The resulting benchmark data and models will be released as open resources, in support of further research on digital trials and AI-assisted clinical research.